



<b>Meeting:</b>	HPB & OG Expert Advisory Group				
<b>Date:</b>	4 April 2018				
<b>Time:</b>	14:00 – 16:00 [HPB] 15:00 – 17:00 [OG]				
<b>Venue:</b>	Evolve Business Centre				
<b>HPB AGENDA</b>					
<b>2:00</b>	<b>1.</b>	<b>INTRODUCTIONS</b>		<b>Lead</b>	<b>Enc</b>
		1.1	Welcome and apologies	JF	
		1.2	Declaration of interest	ALL	
		1.3	Minutes of the previous meeting (4.10.17)	ALL	Enc. 1
	<b>2.</b>	<b>AGENDA ITEMS</b>			
		2.1	Follow up since last meeting <ul style="list-style-type: none"> <li>Chair &amp; Vice Chair Vacancies</li> <li>Electronic Referrals acknowledging Receipt</li> </ul>	JF JF	
		2.2	Trust Representatives (HPB) <ul style="list-style-type: none"> <li>Split into liver and pancreas</li> <li>Radiology representation named?</li> </ul>	ALL	
		2.3	Variation in Pancreatic Cancer Survival (PCUK Data)	ALL	
		2.4	Variation in HCC resection rates <a href="http://tools.england.nhs.uk/images/liveratlas17/atlas.html">http://tools.england.nhs.uk/images/liveratlas17/atlas.html</a>	ALL	
		2.5	HPB North Meeting <ul style="list-style-type: none"> <li>12 September 2018, JCUH</li> </ul>	ALL	
		2.6	Regional MDM for treatment of Refractory IgG4 related disease with Rituximab	ALL	
		2.7	Regional HPB Strategy <ul style="list-style-type: none"> <li>Outreach Models</li> <li>Time Line</li> </ul>	ALL	
		2.8	Clinical Guidelines <ul style="list-style-type: none"> <li>HPB Guidelines (review date May 2017)</li> <li>NICE Guidance for Pancreatic Cancer</li> <li>Specific Guidelines <ul style="list-style-type: none"> <li>Pancreatic cysts – distribute</li> <li>GP Polyps – formulate</li> <li>Double duct sign with normal LFT and no mass – formulate</li> <li>Colorectal metastases – update and distribute</li> </ul> </li> </ul>	ALL	
		2.9	Clinical governance issues	ALL	
		2.10	Patient & Carer Update		
<b>3:00</b>	<b>3.</b>	<b>JOINT HPB &amp; OG NETWORK UPDATES</b>			
		3.1	Cancer Alliance Update <ul style="list-style-type: none"> <li>One Year On Event Feedback</li> <li>Transformation Funding</li> <li>Work Programme</li> <li>28 Day diagnosis</li> </ul>	AF / KE	
		3.2	Performance Data	LW	
		3.3	National 'Best Practice Timed' Oesophago-gastric Cancer Pathway	ALL	Enc. 2 a, b, c (Separate docs)

		3.4	2ww Suspected Cancer Referral Form • To be signed off	KE	
		3.5	Terms of Reference • Review and Sign off	ALL	Enc. 3
		3.6	Campaigns • Bowel Cancer Screening Consultation	ALL	
		3.7	STP Upper GI Pathway Guidance	JP	Enc. 4
	<b>4</b>	<b>NEXT MEETING</b>			
		4.1	<b>Wednesday 3 October 2018, 14.00-17.00</b> <b>Venue – Evolve Business Centre</b>		
<b>3:55</b>	<b>BREAK</b>				
<b>OG AGENDA</b>					
<b>4:00</b>	<b>5</b>	<b>INTRODUCTIONS</b>		<b>Lead</b>	<b>Enc</b>
		5.1	Welcome and apologies	JP	
		5.2	Declaration of interest	ALL	
		5.3	Minutes of the previous meeting (4.10.17)	ALL	Enc. 1
	<b>6</b>	<b>AGENDA ITEMS</b>			
		6.1	Follow up since last meeting • 2ww Endoscopy Form • OG Audit Day	KE	Enc. 5
		6.2	STP Upper GI Pathway Guidance • Significant isolated OG issues	ALL	
		6.3	Open Access Endoscopy Referral Form	JP	Enc. 6
		6.4	Sunderland Audit on Fast Track Clinic Patient Survey (following direct to test OGD & CT)	JP	
		6.5	Proposed patient pathways to comply with new 28 day standard	JP	
		6.6	BSG Guidance of Standards in Upper GI Endoscopy	JP	Enc. 7
		6.7	Updates from Each Centre	ALL	
		6.8	Clinical Guidelines	ALL	
		6.9	Clinical governance issues	ALL	
		6.10	Patient & Carer update		
<b>5:00</b>	<b>7.</b>	<b>Close of meeting</b>			